20/20 Biolabs Inc.
AIDX
Rank in Stocks
#31824
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Share Price
$0.2249
Last synced: 2026-11-11
Market Cap
$2.43M
Change (1 day)
14.98%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade 20/20 Biolabs Inc. (AIDX)
Category
Healthcare
Operating Margin for 20/20 Biolabs Inc. (AIDX)
Operating Margin as of November 2026 TTM: -215.69%
According to 20/20 Biolabs Inc.'s latest financial reports, its current operating margin (TTM) is -215.69%. At the end of 2025 the company had an operating margin of -162.87%.
Operating Margin history for 20/20 Biolabs Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -215.69% | 32.43% |
| 2025 | -162.87% | -49.59% |
| 2024 | -323.06% | -27.67% |
| 2023 | -446.64% | -3,042.29% |
| 2022 | 15.18% | -24.78% |
| 2021 | 20.18% | -123.16% |
| 2020 | -87.13% | -89.82% |
| 2019 | -855.81% | 60.83% |
| 2018 | -532.12% | 30.29% |
| 2017 | -408.42% | -21.82% |
| 2016 | -522.44% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.34% | -100.07% |
US
|
|
| 9.60% | -100.04% |
DE
|
|
| 19.85% | -100.09% |
US
|
|
| 18.76% | -100.09% |
SA
|
|
| 6.10% | -100.03% |
CN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about 20/20 Biolabs Inc.'s operating margin
What is 20/20 Biolabs Inc.'s operating margin?
20/20 Biolabs Inc.'s operating margin is -215.69%, as of Nov 2026.
What was 20/20 Biolabs Inc.'s operating margin in 2025?
In 2025, 20/20 Biolabs Inc.'s operating margin was -162.87%, compared with -323.06% in 2024.
How has 20/20 Biolabs Inc.'s operating margin changed since 2020?
From 2020 to 2025, 20/20 Biolabs Inc.'s operating margin was highest in 2021 (20.18%) and lowest in 2023 (-446.64%).
How does 20/20 Biolabs Inc.'s operating margin compare with similar companies?
20/20 Biolabs Inc.'s operating margin (-215.69%) is lower than that of all 5 similar companies listed above. The highest among them is Tenet Healthcare Corporation, with 19.85%.